81 related articles for article (PubMed ID: 19563407)
21. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.
Gupta S; Johnson SH; Vasmatzis G; Porath B; Rustin JG; Rao P; Costello BA; Leibovich BC; Thompson RH; Cheville JC; Sukov WR
Mod Pathol; 2017 Jul; 30(7):998-1012. PubMed ID: 28338654
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.
Ou Y; Xia R; Kong F; Zhang X; Yu S; Jiang L; Zheng L; Lin L
Oncol Lett; 2016 Mar; 11(3):1823-1828. PubMed ID: 26998084
[TBL] [Abstract][Full Text] [Related]
23. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
24. The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C; Gullberg U
Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
[TBL] [Abstract][Full Text] [Related]
25. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
26. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
27. High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.
Wang X; Lin L; Ren X; Lin Z; Li Z; Li C; Jin T
Int J Clin Exp Pathol; 2014; 7(8):5016-23. PubMed ID: 25197373
[TBL] [Abstract][Full Text] [Related]
28. The role of DEK protein in hepatocellular carcinoma for progression and prognosis.
Lin LJ; Chen LT
Pak J Med Sci; 2013 May; 29(3):778-82. PubMed ID: 24353627
[TBL] [Abstract][Full Text] [Related]
29. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.
Lin L; Piao J; Gao W; Piao Y; Jin G; Ma Y; Li J; Lin Z
BMC Cancer; 2013 Jul; 13():366. PubMed ID: 23902796
[TBL] [Abstract][Full Text] [Related]
30. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
[TBL] [Abstract][Full Text] [Related]
31. Control of tumorigenesis and chemoresistance by the DEK oncogene.
Riveiro-Falkenbach E; Soengas MS
Clin Cancer Res; 2010 Jun; 16(11):2932-8. PubMed ID: 20501624
[TBL] [Abstract][Full Text] [Related]
32. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
33. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
34. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature.
Chamberlin MD; Eltabbakh GH; Mount SL; Leavitt BJ
Gynecol Oncol; 2001 Jul; 82(1):212-5. PubMed ID: 11426990
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
37. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
